Xencor | XNCR - Selling And Administration Expenses


Xencor reported $77.54M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.63B 54M Jun/2026
Alnylam Pharmaceuticals USD 347.92M 65.41M Jun/2026
Amgen USD 1.72B 134M Jun/2026
Arrowhead Research USD 46.63M 4.88M Jun/2026
AstraZeneca USD 5.8B 735M Jun/2026
Biogen USD 709.7M 155.4M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Cytokinetics USD 104.4M 499K Jun/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
J&J USD 6.25B 168M Sep/2026
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
MacroGenics USD 9.71M 1.77M Mar/2026
Merck USD 2.89B 219M Jun/2026
Novartis USD 3.24B 101M Jun/2026
Pfizer USD 3.41B 496M Jun/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Xencor USD 77.54M 4.59M Jun/2026